AstraZeneca PLC (AZN) vs GSK plc (GSK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AZN | GSK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Size band | MEGA | LARGE |
| Listing | NYSE | NYSE |
| Country | United Kingdom | United Kingdom |
| Theme | oncology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $172.06 | $51.10 |
| Return · 1 week | +4.95% | +3.32% |
| Return · 1 month | +3.56% | +2.82% |
| Return · 3 months | −0.24% | −4.86% |
| Return · year to date | −5.07% | +4.74% |
| Return · 1 year | +3.41% | +19.72% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −19.11% | −17.18% |
| 52-week high | $212.71 | $61.70 |
| 52-week low | $153.41 | $42.85 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $266.85B | $101.68B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $527.20M | $158.70M |
| Employees | 96,100 | 66,841 |
| Valuation | ||
| Price to earnings · trailing | 23.80× | 15.62× |
| Price to earnings · forward | 13.77× | 10.06× |
| Price to sales | 4.02× | 2.99× |
| Price to book | 4.91× | 4.22× |
| Enterprise value to EBITDA | 13.62× | 10.53× |
| Enterprise value to revenue | 4.49× | 3.43× |
| PEG ratio | 1.12 | 6.03 |
| Earnings per share · trailing | 6.69 | 3.17 |
| Profitability | ||
| Gross margin | 81.88% | 72.73% |
| Operating margin | 23.46% | 30.94% |
| Profit margin | 17.02% | 14.52% |
| Return on equity | 21.97% | 33.38% |
| Return on assets | 8.21% | 10.01% |
| Growth | ||
| Revenue growth | +6.40% | +5.30% |
| Earnings growth | +2.50% | −69.50% |
| Balance sheet and payout | ||
| Debt / equity (%) | 64.23 | 106.50 |
| Current ratio | 0.89 | 0.82 |
| Dividend yield | 2.00% | 3.67% |
| Payout ratio | 46.95% | 56.55% |
| Trend and volatility | ||
| RSI · 14 | 63.26 | 61.33 |
| ADX · 14 | 16.48 | 22.21 |
| 50-day average | $163.39 | $49.60 |
| 200-day average | $180.45 | $52.36 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.21% | 2.07% |
The full AZN analysis
Everything this table leaves out for AstraZeneca PLC: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AZN argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AZN analysisThe full GSK analysis
Everything this table leaves out for GSK plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GSK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GSK analysis